

V. Balasubramanian

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Sep 17 IMSworld Pharmaceutical Company Directory name change
to PHARMASEARCH
NEWS 3 Oct 09 Korean abstracts now included in Derwent World Patents
Index
NEWS 4 Oct 09 Number of Derwent World Patents Index updates increased
NEWS 5 Oct 15 Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS 6 Oct 22 Over 1 million reactions added to CASREACT
NEWS 7 Oct 22 DGENE GETSIM has been improved
NEWS 8 Oct 29 AAASD no longer available
NEWS 9 Nov 19 New Search Capabilities USPATFULL and USPAT2
NEWS 10 Nov 19 TOXCENTER(SM) - new toxicology file now available on STN
NEWS 11 Nov 29 COPPERLIT now available on STN
NEWS 12 Nov 29 DWPI revisions to NTIS and US Provisional Numbers
NEWS 13 Nov 30 Files VETU and VETB to have open access
NEWS 14 Dec 10 WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS 15 Dec 10 DGENE BLAST Homology Search
NEWS 16 Dec 17 WELDASEARCH now available on STN
NEWS 17 Dec 17 STANDARDS now available on STN
NEWS 18 Dec 17 New fields for DPCI
NEWS 19 Dec 19 CAS Roles modified
NEWS 20 Dec 19 1907-1946 data and page images added to CA and Cplus
NEWS 21 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 22 Jan 25 Searching with the P indicator for Preparations
NEWS 23 Jan 29 FSTA has been reloaded and moves to weekly updates
NEWS 24 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update
frequency
NEWS 25 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

V. Balasubramanian

FILE 'HOME' ENTERED AT 15:59:22 ON 21 FEB 2002

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'REGISTRY' ENTERED AT 15:59:32 ON 21 FEB 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 19 FEB 2002 HIGHEST RN 393780-00-2

DICTIONARY FILE UPDATES: 19 FEB 2002 HIGHEST RN 393780-00-2

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

The P indicator for Preparations was not generated for all of the
CAS Registry Numbers that were added to the H/Z/CA/CAplus files between
12/27/01 and 1/23/02. Use of the P indicator in online and SDI searches
during this period, either directly appended to a CAS Registry Number
or by qualifying an L-number with /P, may have yielded incomplete results.
As of 1/23/02, the situation has been resolved. Also, note that searches
conducted using the PREP role indicator were not affected.

Customers running searches and/or SDIs in the H/Z/CA/CAplus files
incorporating CAS Registry Numbers with the P indicator between 12/27/01
and 1/23/02, are encouraged to re-run these strategies. Contact the
CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698,
worldwide, or send an e-mail to help@cas.org for further assistance or to
receive a credit for any duplicate searches.

=>

Uploading 09636519.str

L1 STRUCTURE UPLOADED


=> d l1

L1 HAS NO ANSWERS

L1 STR

09/636,519

V. Balasubramanian



G1 O, S, N

G2 C, O, S

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 16:00:25 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 396 TO ITERATE

100.0% PROCESSED 396 ITERATIONS

13 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 6727 TO 9113

PROJECTED ANSWERS: 44 TO 476



L2 13 SEA SSS SAM L1

=> d scan

L2 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN 1-Phthalazinamine, N-[2-(4-chlorophenyl)ethyl]-4-(4-pyridinylmethyl)-
(9CI)

MF C22 H19 Cl N4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):13

L2 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN 1-Phthalazinamine, 4-(4-pyridinylmethyl)-N-[3-(trifluoromethyl)phenyl]-
(9CI)


MF C21 H15 F3 N4

V. Balasubramanian



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylsulfonyl)- (9CI)
MF C19 H13 Cl N4 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

V. Balasubramanian

L2 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN 1-Phthalazinamine, N-[3-(decyloxy)phenyl]-4-(4-pyridinylmethyl)- (9CI)

MF C30 H36 N4 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN 1-Phthalazinamine, N-(4-methylphenyl)-4-(4-pyridinylmethyl)- (9CI)

MF C21 H18 N4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

09/636,519

V. Balasubramanian


L2 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Phthalazinamine, N-(3-bromo-4-methylphenyl)-4-[(2-methyl-4-pyridinyl)methyl]- (9CI)
MF C22 H19 Br N4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Phthalazinamine, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI)
MF C21 H14 F4 N4


V. Balasubramanian



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Phthalazinamine, N-(1-phenylethyl)-4-(phenylmethyl)-, (R)- (9CI)
MF C23 H21 N3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Phthalazinamine, N-[3-(2-methyl-1,3-dioxolan-2-yl)phenyl]-4-(4-pyridinylmethyl)- (9CI)
MF C24 H22 N4 O2

V. Balasubramanian



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[(2,6-dimethyl-4-pyridinyl)methyl]-
(9CI)
MF C22 H19 Cl N4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


V. Balasubramanian

L2 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Phthalazinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-7-methyl-4-(4-
pyridinylmethyl)- (9CI)
MF C22 H16 Cl F3 N4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN 1-Phthalazinamine, 4-(4-pyridinylmethyl)-N-[3-(1,1,2,2-
tetrafluoroethoxy)phenyl]- (9CI)
MF C22 H16 F4 N4 O



V. Balasubramanian

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 13 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Acetamide, N-[4-[(3,4-dichlorophenyl)amino]-1-(4-pyridinylmethyl)-6-phthalazinyl]-, monohydrochloride (9CI)
MF C22 H17 Cl2 N5 O . Cl H



ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful
FULL SEARCH INITIATED 16:01:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 7885 TO ITERATE

100.0% PROCESSED 7885 ITERATIONS
SEARCH TIME: 00.00.03

267 ANSWERS

L3 267 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
140.86	141.01

FILE 'CAPLUS' ENTERED AT 16:01:23 ON 21 FEB 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

09/636,519

V. Balasubramanian

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Feb 2002 VOL 136 ISS 8
FILE LAST UPDATED: 20 Feb 2002 (20020220/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 33 L3

=> d 14 1-33 bib hitstr

L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 2001:935442 CAPLUS

DN 136:74621

TI Combinations and compositions which interfere with VEGF/VEGF receptor and angiopoietin/Tie receptor function and their use

IN Siemeister, Gerhard; Haberey, Martin; Thierauch, Karl-Heinz

PA Schering Aktiengesellschaft, Germany

SO PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001097850	A2	20011227	WO 2001-EP6976	20010620
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1166798	A1	20020102	EP 2000-250194	20000623
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	EP 1166799	A1	20020102	EP 2000-250214	20000628
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRAI	EP 2000-250194	A	20000623		
	EP 2000-250214	A	20000628		
OS	MARPAT 136:74621				
IT	212142-18-2				
	RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
		(compns. which interfere with VEGF/VEGF receptor and angiopoietin/Tie			

V. Balasubramanian

receptor function and their use as angiogenesis inhibitors)


RN 212142-18-2 CAPLUS

CN Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 212141-54-3

CMF C20 H15 Cl N4



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

L4 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 2001:889398 CAPLUS

TI Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro

AU Tille, J.-C.; Wood, J.; Mandriota, S. J.; Schnell, C.; Ferrari, S.; Mestan, J.; Zhu, Z.; Witte, L.; Pepper, M. S.

CS Dep. Morphol., Geneva Univ. Med. Cent., Basel, Switz.

SO Journal of Pharmacology and Experimental Therapeutics (2001), 299(3), 1073-1085

CODEN: JPETAB; ISSN: 0022-3565

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

V. Balasubramanian

IT 212142-18-2, ZK 222584

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(VEGF receptor-2 antagonists inhibit VEGF- and basic FGF-induced angiogenesis in vivo and in vitro)


RN 212142-18-2 CAPLUS

CN Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 212141-54-3

CMF C20 H15 Cl N4



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 2001:851122 CAPLUS

DN 135:371759

TI Preparation of N-imidazolylphenyl-5,6-dihydrobenzo[h]quinazolin-4-amines and other N-containing heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders

IN Yamada, Akira; Spears, Glen; Hayashida, Hisashi; Tomishima, Masaki; Ito, Kiyotaka; Imanishi, Masashi

V. Balasubramanian

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 154 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001087845	A2	20011122	WO 2001-JP4002	20010514
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	AU 2000-7501	A	20000515		
	AU 2000-1955	A	20001207		
OS	MARPAT 135:371759				
IT	374555-58-5P , (4-Benzylphthalazin-1-yl) (3-imidazol-1-ylphenyl)amine 374556-51-1P , N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-4-(4-fluorobenzyl)-1-phthalazinamine 374556-52-2P , 4-Benzyl-N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-1-phthalazinamine 374556-56-6P , N-[3-(1,2-Dimethyl-1H-imidazol-5-yl)phenyl]-4-phenoxy-1-phthalazinamine RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of N-(imidazolylphenyl)dihydrobenzo[h]quinazolinamines and other N-contg. heterocyclic amines as 5-hydroxytryptamine antagonists for treatment of CNS disorders)				
RN	374555-58-5	CAPLUS			
CN	1-Phthalazinamine, N-[3-(1H-imidazol-1-yl)phenyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)				



RN 374556-51-1 CAPLUS


CN 1-Phthalazinamine, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-4-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 374556-52-2 CAPLUS


CN 1-Phthalazinamine, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 374556-56-6 CAPLUS

CN 1-Phthalazinamine, N-[3-(1,2-dimethyl-1H-imidazol-5-yl)phenyl]-4-phenoxy- (9CI) (CA INDEX NAME)

V. Balasubramanian



L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 2001:747637 CAPLUS
DN 135:269444
TI Improved treatment of neovascularization
IN Brazzell, Romulus Kimbro
PA Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.
SO PCT Int. Appl., 8 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001074389	A2	20011011	WO 2001-EP3265	20010322
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2000-191807 P 20000324


IT 212141-54-3, CGP 79787

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of neovascularization with combination of angiogenesis inhibitors and photodynamic therapy)

RN 212141-54-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



L4 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 2001:573541 CAPLUS

DN 135:147425

TI Method for treating ocular neovascular diseases using phthalazines in
prepn. of medicaments

IN Brazzell, Romulus Kimbro; Wood, Jeanette Marjorie; Campochiaro, Peter
Anthony; Kane, Frances Elizabeth

PA Ciba Vision Corporation, USA

SO U.S., 19 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6271233	B1	20010807	US 1999-371746	19990810

OS MARPAT 135:147425

IT **212141-51-0P 212141-52-1P**


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)

(method for treating ocular neovascular diseases using phthalazines in
prepn. of medicaments in relation to blockade of VEGF signaling)


RN 212141-51-0 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-52-1 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




IT 212141-57-6 212141-58-7 212141-59-8
212141-60-1 212141-64-5 212141-66-7
212141-67-8 212141-68-9 212141-69-0
212141-70-3 212141-72-5 212141-73-6
212141-74-7 212141-75-8 212141-88-3
212141-91-8 212141-92-9 212142-18-2, CGP
79787D 212142-81-9 212142-82-0
RL: BAC (Biological activity or effector, except adverse); THU

V. Balasubramanian

(Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treating ocular neovascular diseases using phthalazines in
prepn. of medicaments in relation to blockade of VEGF signaling)


RN 212141-57-6 CAPLUS

CN 1-Phthalazinamine, N-(phenylmethyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)



RN 212141-58-7 CAPLUS


CN 1-Phthalazinamine, N-(4-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)



RN 212141-59-8 CAPLUS


CN 1-Phthalazinamine, N-[3-(phenylmethoxy)phenyl]-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-60-1 CAPLUS


CN 1-Phthalazinamine, N-(3-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212141-64-5 CAPLUS


CN 1-Phthalazinamine, N-(2-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-66-7 CAPLUS


CN 1-Phthalazinamine, 4-(4-pyridinylmethyl)-N-[4-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)



RN 212141-67-8 CAPLUS


CN 1-Phthalazinamine, N-(4-fluorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212141-68-9 CAPLUS


CN Phenol, 3-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA INDEX NAME)



RN 212141-69-0 CAPLUS


CN Phenol, 4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-70-3 CAPLUS


CN 1,3-Benzenediamine, N-[4-(4-pyridinylmethyl)-1-phthalazinyl]- (9CI) (CA INDEX NAME)



RN 212141-72-5 CAPLUS


CN 1-Phthalazinamine, N-(3,4-dichlorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-73-6 CAPLUS


CN 1-Phthalazinamine, N-(4-bromophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 212141-74-7 CAPLUS

CN 1-Phthalazinamine, N-(3-chloro-4-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 212141-75-8 CAPLUS
CN Benzonitrile, 4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA
INDEX NAME)




RN 212141-88-3 CAPLUS
CN 1-Phthalazinamine, N-(4-methylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212141-91-8 CAPLUS


CN 1-Phthalazinamine, N-(3-chloro-4-fluorophenyl)-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 212141-92-9 CAPLUS

CN 1-Phthalazinamine, N-(3-methylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian




RN 212142-18-2 CAPLUS

CN Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 212141-54-3

CMF C20 H15 Cl N4



CM 2

CRN 110-15-6


CMF C4 H6 O4

V. Balasubramanian

$\text{HO}_2\text{C}-\text{CH}_2-\text{CH}_2-\text{CO}_2\text{H}$


RN 212142-81-9 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212142-82-0 CAPLUS

CN 1-Phthalazinamine, N-phenyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 2001:489219 CAPLUS

DN 135:71265

TI Combinations of a receptor tyrosine kinase inhibitor with an organic compound capable of binding to .alpha.1-acidic glycoprotein

IN Gambacorti-Passerini, Carlo; Lecoutre, Philipp

09/636,519

V. Balasubramanian

PA Novartis A.-G., Switz.; Novartis-Erfindungen

SO PCT Int. Appl., 79 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047507	A2	20010705	WO 2000-EP13161	20001222
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	IT 1999-MI2711	A	19991227		
OS	MARPAT 135:71265				
IT	212141-54-3				
	RL:	PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)			
		(antitumor combinations of a receptor tyrosine kinase inhibitor with an org. compd. capable of binding to .alpha.1-acidic glycoprotein)			
RN	212141-54-3	CAPLUS			
CN	1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-	(9CI) (CA INDEX NAME)			



L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 2001:115142 CAPLUS

DN 134:163049

TI Preparation of substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

V. Balasubramanian

IN Dumas, Jacques P.; Hatoum-mokdad, Holia N.; Joe, Teddy Kite; Kluender, Harold C. E.; Lee, Wendy; Nagarathnam, Dhanapalan; Sibley, Robert N.; Su, Ning; Boyer, Stephen James

PA Bayer Corporation, USA

SO PCT Int. Appl., 118 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010859	A1	20010215	WO 2000-US21579	20000808
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 1999-371322	A	19990810		
OS	MARPAT 134:163049				
IT	325781-16-6P 325781-17-7P 325781-21-3P 325781-22-4P 325781-23-5P 325781-24-6P 325781-25-7P 325781-26-8P 325781-27-9P 325781-28-0P 325781-29-1P 325781-32-6P 325781-33-7P 325781-35-9P 325781-37-1P 325781-38-2P				
	RL:	BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
		(prepn. of substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity)			
RN	325781-16-6	CAPLUS			
CN	2-Pyridinecarboxamide, 4-[[4-[(4-chlorophenyl)amino]-1-phthalazinyl]methyl]-N-methyl-	(9CI) (CA INDEX NAME)			

V. Balasubramanian




RN 325781-17-7 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[(4-chlorophenyl)amino]-1-phthalazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 325781-21-3 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[(3-bromophenyl)amino]-1-phthalazinyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 325781-22-4 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[4-[(3-bromophenyl)amino]-1-phthalazinyl]methyl]-
(9CI) (CA INDEX NAME)



RN 325781-23-5 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[(2-phenyl-4-pyridinyl)methyl]-
(9CI) (CA INDEX NAME)


V. Balasubramanian




RN 325781-24-6 CAPLUS
CN 1-Phthalazinamine, 4-(4-pyridinylmethyl)-N-[4-(4-pyridinyloxy)phenyl]-
(9CI) (CA INDEX NAME)

PAGE 1-A






RN 325781-25-7 CAPLUS
CN 1-Phthalazinamine, N-(2,3-dihydro-1H-inden-5-yl)-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 325781-26-8 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[(4-chlorophenyl)amino]-1-phthalazinyl]methyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



RN 325781-27-9 CAPLUS
CN 2-Pyridinecarboxamide, 4-[[4-[(4-chlorophenyl)amino]-1-phthalazinyl]methyl]-N-methyl-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 325781-16-6
CMF C22 H18 Cl N5 O




V. Balasubramanian

CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 325781-28-0 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[(4-chlorophenyl)amino]-1-phthalazinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 325781-29-1 CAPLUS


CN 2-Pyridinecarboxamide, 4-[[4-[(4-chlorophenyl)amino]-1-phthalazinyl]methyl]-, dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 325781-17-7

CMF C21 H16 Cl N5 O


V. Balasubramanian



CM 2



CRN 75-75-2

CMF C H4 O3 S





RN 325781-32-6 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[[5-(4-pyridinyl)-1H-1,2,4-triazol-3-yl]thio]- (9CI) (CA INDEX NAME)




RN 325781-33-7 CAPLUS
CN 1-Phthalazinamine, N-[4-(1-methylethyl)phenyl]-4-[[5-(4-pyridinyl)-1H-1,2,4-triazol-3-yl]thio]- (9CI) (CA INDEX NAME)




RN 325781-35-9 CAPLUS
CN 1-Phthalazineacetonitrile, 4-[(2,3-dihydro-1H-inden-5-yl)amino]-.alpha.-4-pyridinyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 325781-37-1 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylsulfonyl)- (9CI) (CA
INDEX NAME)



RN 325781-38-2 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylsulfonyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian




IT 212141-54-3 212142-31-9

RL: RCT (Reactant)

(prepn. of substituted pyridazines and fused pyridazines with
angiogenesis inhibiting activity)

RN 212141-54-3 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)



RN 212142-31-9 CAPLUS

CN 1-Phthalazinamine, N-(3-bromophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)


V. Balasubramanian



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 2000:872655 CAPLUS
DN 134:207774
TI Phthalazine PDE4 inhibitors. Part 2: The synthesis and biological
evaluation of 6-methoxy-1,4-disubstituted derivatives
AU Napoletano, M.; Norcini, G.; Pellacini, F.; Marchini, F.; Morazzoni, G.;
Ferlenga, P.; Pradella, L.
CS Zambon Group, Inpharzam Ricerche, Taverne, 6807, Switz.
SO Bioorg. Med. Chem. Lett. (2000), Volume Date 2001, 11(1), 33-37
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
IT **328941-80-6**
RL: BAC (Biological activity or effector, except adverse); BIOL
(Biological study)
(prepn. of 6-methoxy-1,4-disubstituted phthalazine derivs. as PDE4
inhibitors)
RN 328941-80-6 CAPLUS
CN Phthalazine, 4-(cyclopentyloxy)-1-[(3,5-dichloro-4-pyridinyl)methyl]-6-
methoxy- (9CI) (CA INDEX NAME)

V. Balasubramanian




IT 256443-30-8P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of 6-methoxy-1,4-disubstituted phthalazine derivs. as PDE4 inhibitors)

RN 256443-30-8 CAPLUS

CN Phthalazine, 1-[(3,5-dichloro-4-pyridinyl)methyl]-6-methoxy-4-phenoxy-
(9CI) (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 2000:867326 CAPLUS

DN 135:28529

TI Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy

AU Wood, Jeanette M.

CS Oncology Research, Novartis Pharma AG, Basel, CH 4002, Switz.

SO Medicina (Buenos Aires) (2000), 60(Supl. 2), 41-47

CODEN: MEDCAD; ISSN: 0025-7680

PB Sociedad Argentina de Investigacion Clinica

V. Balasubramanian

DT Journal; General Review

LA English

IT 212142-18-2, PTK 787

RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of vascular endothelial growth factor (VEGF) as novel
approach for cancer therapy)


RN 212142-18-2 CAPLUS

CN Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-
phthalazinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 212141-54-3

CMF C20 H15 Cl N4



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 2000:725470 CAPLUS

DN 133:296440

TI Preparation of phthalazines for treating inflammatory diseases


IN Bold, Guido; Dawson, King Janet; Frei, Jorg; Heng, Richard; Manley, Paul
William; Wietfeld, Bernhard; Wood, Jeanette Marjorie

V. Balasubramanian

PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft
m.b.H.; Dawson King, Janet
SO PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059509	A1	20001012	WO 2000-EP2726	20000328
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1165085	A1	20020102	EP 2000-920604	20000328
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	BR 2000009507	A	20020115	BR 2000-9507	20000328
	NO 2001004655	A	20011019	NO 2001-4655	20010925
PRAI	CH 1999-603	A	19990330		
	GB 1999-16064	A	19990708		
	WO 2000-EP2726	W	20000328		
OS	MARPAT 133:296440				
IT	212142-75-1P				
	RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of phthalazines for treating inflammatory diseases)				
RN	212142-75-1 CAPLUS				
CN	1-Phthalazinemethanol, 4-[(4-chlorophenyl)amino]-.alpha.-4-pyridinyl-(9CI) (CA INDEX NAME)				

V. Balasubramanian



IT 212141-54-3P 212141-74-7P 212142-21-7P
 284031-08-9P 300842-49-3P 300842-50-6P
 300842-51-7P 300842-52-8P 300842-53-9P
 300842-54-0P 300842-55-1P 300842-56-2P
 300842-57-3P 300842-58-4P 300842-59-5P
 300842-60-8P 300842-61-9P 300842-62-0P
 300842-63-1P 300842-64-2P 300842-65-3P
 300842-66-4P 300842-67-5P 300842-68-6P
 300842-69-7P 300842-70-0P 300842-71-1P
 300842-73-3P 300842-74-4P 300842-76-6P
 300842-77-7P 300842-83-5P 300842-90-4P
 300842-91-5P 300842-92-6P 300842-93-7P
 300842-94-8P 300842-95-9P 300842-96-0P
 300842-97-1P 300842-98-2P 300842-99-3P
 300843-00-9P 300843-01-0P 300843-02-1P
 300843-03-2P 300843-04-3P 300843-05-4P
 300843-06-5P 300843-07-6P 300843-09-8P
 300843-10-1P 300843-12-3P 300843-13-4P
 300843-15-6P 300843-16-7P 300843-17-8P
 300843-18-9P 300843-19-0P 300843-20-3P
 300843-21-4P 300843-22-5P 300843-23-6P
 300843-24-7P 300843-25-8P 300843-26-9P
 300843-27-0P 300843-28-1P 300843-29-2P
 300843-32-7P 300843-33-8P 300843-34-9P
 300843-62-3P 300843-63-4P 300843-64-5P
 300843-65-6P 300843-66-7P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phthalazines for treating inflammatory diseases)

RN 212141-54-3 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-74-7 CAPLUS


CN 1-Phthalazinamine, N-(3-chloro-4-methoxyphenyl)-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)




RN 212142-21-7 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[(1-oxido-4-pyridinyl)methyl]-
(9CI) (CA INDEX NAME)

V. Balasubramanian




RN 284031-08-9 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-7-methyl-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)




RN 300842-49-3 CAPLUS
CN 1-Phthalazinamine, N-(3-methoxy-4-methylphenyl)-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300842-50-6 CAPLUS


CN 1-Phthalazinamine, 4-(4-pyridinylmethyl)-N-[3-(trifluoromethyl)thio]phenyl- (9CI) (CA INDEX NAME)



RN 300842-51-7 CAPLUS


CN Benzamide, N-methyl-4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 300842-52-8 CAPLUS


CN 1-Phthalazinamine, N-[3-(1H-pyrazol-3-yl)phenyl]-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 300842-53-9 CAPLUS


CN 1-Phthalazinamine, N-[3-(1-methyl-1H-pyrazol-3-yl)phenyl]-4-(4-
pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300842-54-0 CAPLUS


CN Benzoic acid, 4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 300842-55-1 CAPLUS


CN 1-Phthalazinamine, N-[3,5-bis(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300842-56-2 CAPLUS


CN 1-Phthalazinamine, N-[3-chloro-5-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 300842-57-3 CAPLUS


CN 1-Phthalazinamine, N-(4-chloro-3-methylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300842-58-4 CAPLUS


CN 1,3-Benzenedicarboxylic acid, 5-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 300842-59-5 CAPLUS


CN 1-Phthalazinamine, N-[3,4-bis(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300842-60-8 CAPLUS


CN 1-Phthalazinamine, N-[4-bromo-3-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 300842-61-9 CAPLUS


CN 1-Phthalazinamine, N-(3-iodo-4-methylphenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 300842-62-0 CAPLUS


CN 1-Phthalazinamine, N-[4-iodo-3-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 300842-63-1 CAPLUS


CN 1-Phthalazinamine, N-[3-iodo-5-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300842-64-2 CAPLUS


CN 1-Phthalazinamine, N-(3-bromo-4-methylphenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)



RN 300842-65-3 CAPLUS


CN 1-Phthalazinamine, N-[4-fluoro-3-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300842-66-4 CAPLUS


CN 1-Phthalazinamine, N-[4-iodo-3-(1-methylethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 300842-67-5 CAPLUS


CN 1-Phthalazinamine, N-[3-methyl-5-(1-methylethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300842-68-6 CAPLUS


CN 1-Phthalazinamine, N-[3-methyl-5-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 300842-69-7 CAPLUS


CN 1-Phthalazinamine, N-[4-bromo-3-(1-methylethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300842-70-0 CAPLUS


CN 1-Phthalazinamine, N-(4-bromo-3-propylphenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)




RN 300842-71-1 CAPLUS

CN 1-Phthalazinamine, N-[3-bromo-5-(2,2,2-trifluoroethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 300842-73-3 CAPLUS
CN 1-Phthalazinamine, N-(3-bromo-4-ethylphenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)



RN 300842-74-4 CAPLUS
CN 1-Phthalazinamine, N-[3-bromo-4-(1,1-dimethylethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 300842-76-6 CAPLUS

CN Benzoic acid, 2-bromo-4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 300842-75-5


CMF C21 H15 Br N4 O2




CM 2

V. Balasubramanian

CRN 76-05-1
CMF C2 H F3 O2




RN 300842-77-7 CAPLUS
CN Benzoic acid, 2-bromo-4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 300842-83-5 CAPLUS
CN Benzenesulfonamide, 4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI)
(CA INDEX NAME)

V. Balasubramanian




RN 300842-90-4 CAPLUS
CN 1-Phthalazinamine, N-(3,5-dimethylphenyl)-6-methyl-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)




RN 300842-91-5 CAPLUS
CN 1-Phthalazinamine, N-(3,5-dimethylphenyl)-7-methyl-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300842-92-6 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-6-methyl-4-(4-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 300842-93-7 CAPLUS


CN 1-Phthalazinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-6-methyl-4-(4-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300842-94-8 CAPLUS


CN 1-Phthalazinamine, N-[3-bromo-5-(trifluoromethyl)phenyl]-6-methyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 300842-95-9 CAPLUS


CN 1-Phthalazinamine, N-[4-bromo-3-(trifluoromethyl)phenyl]-6-methyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300842-96-0 CAPLUS


CN 1-Phthalazinamine, N-(3-iodo-4-methylphenyl)-6-methyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 300842-97-1 CAPLUS

CN 1-Phthalazinamine, N-(4-chloro-3-methoxyphenyl)-6-methyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)


V. Balasubramanian



RN 300842-98-2 CAPLUS

CN 1-Phthalazinamine, N-[trans-4-(1,1-dimethylethyl)cyclohexyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 300842-99-3 CAPLUS

CN 1-Phthalazinamine, N-[cis-4-(1,1-dimethylethyl)cyclohexyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.

V. Balasubramanian



RN 300843-00-9 CAPLUS


CN 1-Phthalazinamine, N-[(4-methylphenyl)methyl]-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)



RN 300843-01-0 CAPLUS


CN 1-Phthalazinamine, N-[(4-chlorophenyl)methyl]-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 300843-02-1 CAPLUS


CN 1-Phthalazinamine, N-[(3-methylphenyl)methyl]-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)




RN 300843-03-2 CAPLUS

CN 1-Phthalazinamine, N-[(2-methylphenyl)methyl]-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian




RN 300843-04-3 CAPLUS
CN 1-Phthalazinamine, 4-(4-pyridinylmethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 300843-05-4 CAPLUS
CN 1-Phthalazinamine, N-[(2-chlorophenyl)methyl]-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 300843-06-5 CAPLUS


CN 1-Phthalazinamine, 4-(4-pyridinylmethyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 300843-07-6 CAPLUS

CN 1-Phthalazinamine, N-[(3-chlorophenyl)methyl]-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian




RN 300843-09-8 CAPLUS

CN Butanedioic acid, compd. with N-[(3-ethylphenyl)methyl]-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 300843-08-7

CMF C23 H22 N4




CM 2

V. Balasubramanian

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RN 300843-10-1 CAPLUS
CN 1-Phthalazinamine, N-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 300843-12-3 CAPLUS
CN Butanedioic acid, compd. with N-[(4-ethylphenyl)methyl]-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 300843-11-2
CMF C23 H22 N4

V. Balasubramanian



CM 2



CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H


RN 300843-13-4 CAPLUS

CN 1-Phthalazinamine, N-[2-(4-chlorophenyl)ethyl]-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 300843-15-6 CAPLUS
CN 1-Phthalazinamine, N-(1-naphthalenylmethyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)


V. Balasubramanian



RN 300843-16-7 CAPLUS

CN 1-Phthalazinamine, N-[cis-4-(1-methylethyl)cyclohexyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 300843-17-8 CAPLUS

CN 1-Phthalazinamine, N-[trans-4-(1-methylethyl)cyclohexyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.


V. Balasubramanian



RN 300843-18-9 CAPLUS

CN 1-Phthalazinamine, N-(cis-4-ethylcyclohexyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

Relative stereochemistry.




RN 300843-19-0 CAPLUS

CN 1-Phthalazinamine, N-(trans-4-ethylcyclohexyl)-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)


Relative stereochemistry.

V. Balasubramanian



RN 300843-20-3 CAPLUS


CN Methanone, [4-[(4-chlorophenyl)amino]-1-phthalazinyl]-4-pyridinyl- (9CI)
(CA INDEX NAME)



RN 300843-21-4 CAPLUS


CN 1-Phthalazinemethanol, 4-[(4-chlorophenyl)amino]-.alpha.-(1-oxido-4-pyridinyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300843-22-5 CAPLUS


CN 1-Phthalazinamine, N-[3-bromo-5-(trifluoromethyl)phenyl]-4-[(2-methyl-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 300843-23-6 CAPLUS


CN 1-Phthalazinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[(2-methyl-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300843-24-7 CAPLUS


CN 1-Phthalazinamine, N-[3-chloro-5-(trifluoromethyl)phenyl]-4-[(2-methyl-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 300843-25-8 CAPLUS


CN 1-Phthalazinamine, N-[4-(1,1-dimethylethyl)phenyl]-4-[(2-methyl-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300843-26-9 CAPLUS


CN 1-Phthalazinamine, N-(3-bromo-4-ethylphenyl)-4-[(2-methyl-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 300843-27-0 CAPLUS


CN 1-Phthalazinamine, N-(3-bromo-4-methylphenyl)-4-[(2-methyl-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300843-28-1 CAPLUS


CN 1-Phthalazinamine, N-[3,4-bis(trifluoromethyl)phenyl]-4-[(2-methyl-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 300843-29-2 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(fluoro-4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 300843-32-7 CAPLUS


CN 1-Phthalazinamine, N-(3-bromo-4-methylphenyl)-4-[(1-oxido-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 300843-33-8 CAPLUS


CN Methanone, [4-[(3-bromo-4-methylphenyl)amino]-1-phthalazinyl]-4-pyridinyl- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300843-34-9 CAPLUS


CN 1-Phthalazinemethanol, 4-[(3-bromo-4-methylphenyl)amino]-.alpha.-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 300843-62-3 CAPLUS


CN 1-Phthalazinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-7-methyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300843-63-4 CAPLUS


CN 1-Phthalazinamine, N-[3-bromo-5-(trifluoromethyl)phenyl]-7-methyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 300843-64-5 CAPLUS


CN 1-Phthalazinamine, N-[4-bromo-3-(trifluoromethyl)phenyl]-7-methyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 300843-65-6 CAPLUS


CN 1-Phthalazinamine, N-(3-iodo-4-methylphenyl)-7-methyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 300843-66-7 CAPLUS

CN 1-Phthalazinamine, N-(4-chloro-3-methoxyphenyl)-7-methyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 2000:651216 CAPLUS
DN 133:317318
TI Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
AU Dreys, Joachim; Hofmann, Inga; Hugenschmidt, Harald; Wittig, Christine; Madjar, Helmut; Muller, Marianne; Wood, Jeanette; Martiny-Baron, Georg; Unger, Clemens; Marme, Dieter
CS Department of Medical Oncology, Tumor Biology Center, Freiburg, 79106, Germany
SO Cancer Res. (2000), 60(17), 4819-4824
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
IT 212142-18-2, PTK 787/ZK 222584
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(effects of vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 on primary tumor, metastasis, vessel d., and blood flow in a murine renal cell carcinoma model)
RN 212142-18-2 CAPLUS
CN Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 212141-54-3
CMF C20 H15 Cl N4

V. Balasubramanian




RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 2000:282733 CAPLUS
DN 133:68550
TI PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
AU Wood, Jeanette M.; Bold, Guido; Buchdunger, Elizabeth; Cozens, Robert; Ferrari, Stefano; Frei, Jorg; Hofmann, Francesco; Mestan, Jurgen; Mett, Helmut; O'Reilly, Terence; Persohn, Elke; Rosel, Johannes; Schnell, Christian; Stover, David; Theuer, Andreas; Towbin, Harry; Wenger, Fritz; Woods-Cook, Kathie; Menrad, Andreas; Siemeister, Gerhard; Schirner, Michael; Thierauch, Karl-Heinz; Schneider, Martin R.; Dreves, Joachim; Martiny-Baron, Georg; Totzke, Frank; Marme, Dieter
CS Oncology Research, Novartis Pharma AG, Basel, CH-4002, Switz.
SO Cancer Res. (2000), 60(8), 2178-2189
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
IT 212142-18-2, PTK 787/ZK 222584
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration)
RN 212142-18-2 CAPLUS
CN Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

V. Balasubramanian

CRN 212141-54-3
CMF C20 H15 Cl N4



CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RE.CNT 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 2000:242982 CAPLUS
DN 133:129583
TI Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation
AU Yano, Seiji; Herbst, Roy S.; Shinohara, Hisashi; Knighton, Barbara; Bucana, Corazon D.; Killion, Jerald J.; Wood, Jeanette; Fidler, Isaiah J.
CS Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA
SO Clin. Cancer Res. (2000), 6(3), 957-965
CODEN: CCRE4; ISSN: 1078-0432
PB American Association for Cancer Research
DT Journal
LA English
IT **212142-18-2**, PTK 787/ZK 222584
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

09/636,519

V. Balasubramanian

(effect of PTK 787 on malignant pleural effusion of human lung
adenocarcinoma)


RN 212142-18-2 CAPLUS

CN Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-
phthalazinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 212141-54-3

CMF C20 H15 Cl N4



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 2000:159571 CAPLUS

DN 133:68508

TI Inhibition of malignant ascites and growth of human ovarian carcinoma by
oral administration of a potent inhibitor of the vascular endothelial
growth factor receptor tyrosine kinases

AU Xu, L.; Yoneda, J.; Herrera, C.; Wood, J.; Killion, J. J.; Fidler, I. J.

CS Department of Cancer Biology, The University of Texas M.D. Anderson Cancer
Center, Houston, TX, 77030, USA

SO Int. J. Oncol. (2000), 16(3), 445-454

CODEN: IJONES; ISSN: 1019-6439

V. Balasubramanian

PB International Journal of Oncology

DT Journal

LA English


IT 212141-51-0

RL: BAC (Biological activity or effector, except adverse); BIOL
(Biological study)

(inhibition of malignant ascites and growth of human ovarian carcinoma
by oral administration of a potent inhibitor of the vascular
endothelial growth factor receptor tyrosine kinases)

RN 212141-51-0 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)



RE.CNT 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 2000:133467 CAPLUS

DN 132:175828

TI Method using phthalazine derivatives for treating ocular neovascular
diseases

IN Brazzell, Romulus Kimbro; Wood, Jeanette Marjorie; Campochiaro, Peter
Anthony; Kane, Frances Elizabeth

PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft
m.b.H.

SO PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000009098	A2	20000224	WO 1999-EP5876	19990811
	WO 2000009098	A3	20000518		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,


V. Balasubramanian

CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG,
MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9957330 A1 20000306 AU 1999-57330 19990811
EP 1105136 A2 20010613 EP 1999-944371 19990811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
US 6214819 B1 20010410 US 1999-442781 19991118
PRAI US 1998-133855 A 19980813
WO 1999-EP5876 W 19990811
OS MARPAT 132:175828
IT **212141-51-0P 212141-52-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(phthalazine derivs. for treating ocular neovascular diseases)
RN 212141-51-0 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)



RN 212141-52-1 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

V. Balasubramanian




IT 212141-54-3, CGP 79787D 212141-57-6 212141-58-7
212141-59-8 212141-60-1 212141-64-5
212141-66-7 212141-67-8 212141-68-9
212141-69-0 212141-70-3 212141-72-5
212141-73-6 212141-74-7 212141-75-8
212141-88-3 212141-91-8 212141-92-9
212142-81-9 212142-82-0

RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(phthalazine derivs. for treating ocular neovascular diseases)

RN 212141-54-3 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212141-57-6 CAPLUS

CN 1-Phthalazinamine, N-(phenylmethyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)




Ph-CH₂-NH

RN 212141-58-7 CAPLUS


CN 1-Phthalazinamine, N-(4-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212141-59-8 CAPLUS


CN 1-Phthalazinamine, N-[3-(phenylmethoxy)phenyl]-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 212141-60-1 CAPLUS


CN 1-Phthalazinamine, N-(3-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212141-64-5 CAPLUS


CN 1-Phthalazinamine, N-(2-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212141-66-7 CAPLUS


CN 1-Phthalazinamine, 4-(4-pyridinylmethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-67-8 CAPLUS


CN 1-Phthalazinamine, N-(4-fluorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212141-68-9 CAPLUS


CN Phenol, 3-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-69-0 CAPLUS


CN Phenol, 4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA INDEX NAME)



RN 212141-70-3 CAPLUS


CN 1,3-Benzenediamine, N-[4-(4-pyridinylmethyl)-1-phthalazinyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-72-5 CAPLUS


CN 1-Phthalazinamine, N-(3,4-dichlorophenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)



RN 212141-73-6 CAPLUS


CN 1-Phthalazinamine, N-(4-bromophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212141-74-7 CAPLUS


CN 1-Phthalazinamine, N-(3-chloro-4-methoxyphenyl)-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 212141-75-8 CAPLUS


CN Benzonitrile, 4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212141-88-3 CAPLUS


CN 1-Phthalazinamine, N-(4-methylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212141-91-8 CAPLUS


CN 1-Phthalazinamine, N-(3-chloro-4-fluorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-92-9 CAPLUS


CN 1-Phthalazinamine, N-(3-methylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212142-81-9 CAPLUS


CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-82-0 CAPLUS

CN 1-Phthalazinamine, N-phenyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 2000:84783 CAPLUS

DN 132:122626

TI Preparation of phthalazines as phosphodiesterase 4 inhibitors

IN Napoletano, Mauro; Norcini, Gabriele; Grancini, Giancarlo; Pellacini, Franco; Leali, Gian Marco; Morazzoni, Gabriele

PA Zambon Group S.P.A., Italy

SO PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005218	A1	20000203	WO 1999-EP4904	19990713

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,

V. Balasubramanian

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 9952810 A1 20000214 AU 1999-52810 19990713
 BR 9911175 A 20010320 BR 1999-11175 19990713
 EP 1097142 A1 20010509 EP 1999-938229 19990713
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 NO 2001000331 A 20010320 NO 2001-331 20010119
 US 6329370 B1 20011211 US 2001-743813 20010122
 PRAI IT 1998-MI1670 A 19980721
 WO 1999-EP4904 W 19990713
 OS MARPAT 132:122626
 IT **256443-30-8P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (prepn. of phthalazines as phosphodiesterase 4 inhibitors)
 RN 256443-30-8 CAPLUS
 CN Phthalazine, 1-[(3,5-dichloro-4-pyridinyl)methyl]-6-methoxy-4-phenoxy-
 (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:549262 CAPLUS
 DN 131:184957
 TI Preparation of phthalazine derivatives for treatment of erectile
 dysfunction
 IN Watanabe, Nobuhisa; Karibe, Norio; Miyazaki, Kazuki; Ozaki, Fumihiro;
 Kamada, Atsushi; Miyazawa, Shuhei; Naoe, Yoshimitsu; Kaneko, Toshihiko;
 Tsukada, Itaru; Nagakura, Tadashi; Ishihara, Hiroki; Kodama, Kohtarou;
 Adachi, Hideyuki
 PA Eisai Co., Ltd., Japan
 SO PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DT Patent

V. Balasubramanian

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9942452	A1	19990826	WO 1999-JP688	19990217
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9925470	A1	19990906	AU 1999-25470	19990217
	JP 2000204080	A2	20000725	JP 1999-38445	19990217
	BR 9909369	A	20001128	BR 1999-9369	19990217
	EP 1057819	A1	20001206	EP 1999-905213	19990217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	NO 2000000969	A	20000811	NO 2000-969	20000225
PRAI	JP 1998-37020	A	19980219		
	JP 1998-319540	A	19981110		
	WO 1999-JP688	W	19990217		
OS	MARPAT 131:184957				
IT	240401-46-1P				
	RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of phthalazine derivs. for treatment of erectile dysfunction)				
RN	240401-46-1 CAPLUS				
CN	6-Phthalazinecarbonitrile, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)				



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD

09/636,519

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:568821 CAPLUS
 DN 129:202950
 TI Preparation of 1-arylamino-4-pyridylmethylphthalazines and analogs as VEGF
 receptor inhibitors
 IN Bold, Guido; Frei, Jorg; Traxler, Peter; Altmann, Karl-Heinz; Mett,
 Helmut; Stover, David Raymond; Wood, Jeanette
 PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft
 m.b.H.
 SO PCT Int. Appl., 113 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9835958	A1	19980820	WO 1998-EP764	19980211
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9866218	A1	19980908	AU 1998-66218	19980211
	AU 731852	B2	20010405		
	EP 970070	A1	20000112	EP 1998-908086	19980211
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO			
	BR 9807685	A	20000321	BR 1998-7685	19980211
	JP 2001508800	T2	20010703	JP 1998-535336	19980211
	ZA 9801155	A	19980813	ZA 1998-1155	19980212
	NO 9903888	A	19991011	NO 1999-3888	19990812
	US 6258812	B1	20010710	US 1999-367273	19991020
PRAI	CH 1997-315	A	19970213		
	WO 1998-EP764	W	19980211		
OS	MARPAT 129:202950				
IT	212141-51-0P	212141-52-1P	212141-54-3P		
	212141-55-4P	212141-56-5P	212141-57-6P		
	212141-58-7P	212141-59-8P	212141-60-1P		
	212141-61-2P	212141-62-3P	212141-63-4P		
	212141-64-5P	212141-66-7P	212141-67-8P		
	212141-68-9P	212141-69-0P	212141-70-3P		
	212141-71-4P	212141-72-5P	212141-73-6P		
	212141-74-7P	212141-75-8P	212141-76-9P		
	212141-77-0P	212141-78-1P	212141-79-2P		
	212141-80-5P	212141-81-6P	212141-82-7P		
	212141-83-8P	212141-84-9P	212141-85-0P		
	212141-86-1P	212141-87-2P	212141-88-3P		
	212141-89-4P	212141-90-7P	212141-91-8P		
	212141-92-9P	212141-93-0P	212141-94-1P		
	212141-95-2P	212141-96-3P	212141-97-4P		
	212141-98-5P	212141-99-6P	212142-01-3P		
	212142-02-4P	212142-03-5P	212142-05-7P		
	212142-11-5P	212142-12-6P	212142-13-7P		

V. Balasubramanian


212142-14-8P 212142-15-9P 212142-16-0P
 212142-17-1P 212142-18-2P 212142-19-3P
 212142-20-6P 212142-21-7P 212142-22-8P
 212142-23-9P 212142-24-0P 212142-25-1P
 212142-26-2P 212142-27-3P 212142-28-4P
 212142-29-5P 212142-30-8P 212142-31-9P
 212142-32-0P 212142-33-1P 212142-34-2P
 212142-35-3P 212142-36-4P 212142-37-5P
 212142-38-6P 212142-39-7P 212142-40-0P
 212142-41-1P 212142-42-2P 212142-43-3P
 212142-44-4P 212142-45-5P 212142-46-6P
 212142-47-7P 212142-48-8P 212142-49-9P
 212142-50-2P 212142-51-3P 212142-52-4P
 212142-53-5P 212142-54-6P 212142-55-7P
 212142-56-8P 212142-57-9P 212142-58-0P
 212142-59-1P 212142-60-4P 212142-62-6P
 212142-63-7P 212142-64-8P 212142-65-9P
 212142-66-0P 212142-67-1P 212142-68-2P
 212142-69-3P 212142-74-0P 212142-75-1P
 212142-81-9P 212142-82-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 1-arylamino-4-pyridylmethylphthalazines and analogs as VEGF receptor inhibitors)

RN 212141-51-0 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




RN 212141-52-1 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 212141-54-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 212141-55-4 CAPLUS
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-pyridinylmethyl)-, hydrochloride (5:9) (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-56-5 CAPLUS

CN 1-Phthalazinamine, N-phenyl-4-(4-pyridinylmethyl)-, dihydrochloride (9CI)
(CA INDEX NAME)




● 2 HCl

RN 212141-57-6 CAPLUS


CN 1-Phthalazinamine, N-(phenylmethyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212141-58-7 CAPLUS


CN 1-Phthalazinamine, N-(4-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212141-59-8 CAPLUS


CN 1-Phthalazinamine, N-[3-(phenylmethoxy)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-60-1 CAPLUS


CN 1-Phthalazinamine, N-(3-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212141-61-2 CAPLUS


CN Acetamide, N-[4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-62-3 CAPLUS
CN 1-Phthalazinamine, N-[(1S)-1-phenylethyl]-4-(4-pyridinylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 212141-63-4 CAPLUS
CN 1-Phthalazinamine, N-[(1R)-1-phenylethyl]-4-(4-pyridinylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



● 2 HCl

RN 212141-64-5 CAPLUS


CN 1-Phthalazinamine, N-(2-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212141-66-7 CAPLUS


CN 1-Phthalazinamine, 4-(4-pyridinylmethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-67-8 CAPLUS


CN 1-Phthalazinamine, N-(4-fluorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212141-68-9 CAPLUS


CN Phenol, 3-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-69-0 CAPLUS


CN Phenol, 4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA INDEX NAME)



RN 212141-70-3 CAPLUS

CN 1,3-Benzenediamine, N-[4-(4-pyridinylmethyl)-1-phthalazinyl]- (9CI) (CA INDEX NAME)


V. Balasubramanian



RN 212141-71-4 CAPLUS
CN 1,3-Benzenediamine, N-[4-(4-pyridinylmethyl)-1-phthalazinyl]-,
trimethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 212141-70-3
CMF C20 H17 N5



CM 2


CRN 75-75-2
CMF C H4 O3 S

V. Balasubramanian



RN 212141-72-5 CAPLUS


CN 1-Phthalazinamine, N-(3,4-dichlorophenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)



RN 212141-73-6 CAPLUS


CN 1-Phthalazinamine, N-(4-bromophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212141-74-7 CAPLUS


CN 1-Phthalazinamine, N-(3-chloro-4-methoxyphenyl)-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 212141-75-8 CAPLUS


CN Benzonitrile, 4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212141-76-9 CAPLUS


CN Acetamide, N-[4-[(4-chlorophenyl)amino]-1-(4-pyridinylmethyl)-6-phthalazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 212141-77-0 CAPLUS


CN Acetamide, N-[4-[(4-methoxyphenyl)amino]-1-(4-pyridinylmethyl)-6-phthalazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-78-1 CAPLUS


CN Acetamide, N-[4-[(3-methoxyphenyl)amino]-1-(4-pyridinylmethyl)-6-phthalazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 212141-79-2 CAPLUS


CN Acetamide, N-[4-[(3-chlorophenyl)amino]-1-(4-pyridinylmethyl)-6-phthalazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-80-5 CAPLUS


CN Acetamide, N-[4-(phenylamino)-1-(4-pyridinylmethyl)-6-phthalazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 212141-81-6 CAPLUS


CN Acetamide, N-[4-[(3,4-dichlorophenyl)amino]-1-(4-pyridinylmethyl)-6-phthalazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-82-7 CAPLUS


CN 1,7-Phthalazinediamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



RN 212141-83-8 CAPLUS


CN 1,7-Phthalazinediamine, N1-(3-chlorophenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 212141-84-9 CAPLUS


CN 1,7-Phthalazinediamine, N1-phenyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212141-85-0 CAPLUS


CN 1,7-Phthalazinediamine, N1-(4-methylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-86-1 CAPLUS


CN 1,7-Phthalazinediamine, N1-(4-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)



RN 212141-87-2 CAPLUS


CN 1,7-Phthalazinediamine, N1-(3-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 212141-88-3 CAPLUS

CN 1-Phthalazinamine, N-(4-methylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212141-89-4 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 212141-54-3

CMF C20 H15 Cl N4

V. Balasubramanian




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



RN 212141-90-7 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-,
dimethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 212141-54-3

CMF C20 H15 Cl N4


V. Balasubramanian



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 212141-91-8 CAPLUS


CN 1-Phthalazinamine, N-(3-chloro-4-fluorophenyl)-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-92-9 CAPLUS


CN 1-Phthalazinamine, N-(3-methylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)



RN 212141-93-0 CAPLUS


CN 1-Phthalazinamine, N-(4-ethylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212141-94-1 CAPLUS


CN 1-Phthalazinamine, N-(4-propylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212141-95-2 CAPLUS


CN 1-Phthalazinamine, N-(3-fluoro-4-methylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-96-3 CAPLUS


CN 1-Phthalazinamine, N-(4-chloro-2-fluorophenyl)-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 212141-97-4 CAPLUS


CN 1-Phthalazinamine, N-(4-ethoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212141-98-5 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[(2-methyl-4-pyridinyl)methyl]-
(9CI) (CA INDEX NAME)



RN 212141-99-6 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[(2,6-dimethyl-4-pyridinyl)methyl]-
(9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-01-3 CAPLUS


CN 1-Phthalazinamine, N-(3,4-dimethylphenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)



RN 212142-02-4 CAPLUS


CN 1-Phthalazinamine, N-(3,5-dimethylphenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 212142-03-5 CAPLUS


CN 1-Phthalazinamine, N-[4-(1-methylethyl)phenyl]-4-(4-pyridinylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)



RN 212142-05-7 CAPLUS


CN 1-Phthalazinamine, N-[4-(1,1-dimethylethyl)phenyl]-4-(4-pyridinylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-11-5 CAPLUS


CN 1-Phthalazinamine, N-[1,1'-biphenyl]-4-yl-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)



RN 212142-12-6 CAPLUS

CN 1-Phthalazinamine, 4-(4-pyridinylmethyl)-N-(3,4,5-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian




RN 212142-13-7 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, 3-oxide
(9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 212142-14-8 CAPLUS


CN Phenol, 3-[[4-(4-pyridinylmethyl)-1-phthalazinyl]oxy]- (9CI) (CA INDEX NAME)



RN 212142-15-9 CAPLUS


CN 1-Phthalazinamine, N-cyclohexyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-16-0 CAPLUS


CN 1-Phthalazinamine, N-cyclopentyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212142-17-1 CAPLUS

CN 1-Phthalazinamine, N-cyclopropyl-4-(4-pyridinylmethyl)-, hydrochloride (2:3) (9CI) (CA INDEX NAME)

V. Balasubramanian



● 3/2 HCl


RN 212142-18-2 CAPLUS

CN Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 212141-54-3

CMF C20 H15 Cl N4




CM 2

09/636,519

V. Balasubramanian


CRN 110-15-6
CMF C4 H6 O4



RN 212142-19-3 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, ethanedioate
(1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 212141-54-3
CMF C20 H15 Cl N4




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 212142-20-6 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[1-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-21-7 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[(1-oxido-4-pyridinyl)methyl]-
(9CI) (CA INDEX NAME)



RN 212142-22-8 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyrimidinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212142-23-9 CAPLUS


CN 1-Phthalazinamine, N-(3-phenoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212142-24-0 CAPLUS


CN Phenol, 2-methyl-5-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 212142-25-1 CAPLUS


CN Phenol, 2-methoxy-5-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI)
(CA INDEX NAME)



RN 212142-26-2 CAPLUS


CN 1-Phthalazinamine, N-[3-(methylthio)phenyl]-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 212142-27-3 CAPLUS


CN 1-Phthalazinamine, N-(3-ethylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)



RN 212142-28-4 CAPLUS


CN 1-Phthalazinamine, N-(3-ethoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212142-29-5 CAPLUS


CN 1-Phthalazinamine, 4-(4-pyridinylmethyl)-N-[3-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)



RN 212142-30-8 CAPLUS


CN 1-Phthalazinamine, 4-(4-pyridinylmethyl)-N-[3-(trifluoromethoxy)phenyl]-
(9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-31-9 CAPLUS


CN 1-Phthalazinamine, N-(3-bromophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212142-32-0 CAPLUS


CN Benzenemethanol, 3-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-33-1 CAPLUS


CN Benzenemethanol, .alpha.-methyl-3-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA INDEX NAME)



RN 212142-34-2 CAPLUS


CN 1-Phthalazinamine, N-[3-(1-methylethoxy)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-35-3 CAPLUS


CN 1-Phthalazinamine, N-[3-methoxy-5-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212142-36-4 CAPLUS


CN 1-Phthalazinamine, N-(3,5-dimethoxyphenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 212142-37-5 CAPLUS


CN 1-Phthalazinamine, N-[3-(1,1-dimethylethyl)phenyl]-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 212142-38-6 CAPLUS


CN 1-Phthalazinamine, N-[3-bromo-5-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-39-7 CAPLUS


CN 1-Phthalazinamine, N-[3-(1-methylethyl)phenyl]-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 212142-40-0 CAPLUS


CN 1-Phthalazinamine, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-41-1 CAPLUS


CN 1-Phthalazinamine, 4-(4-pyridinylmethyl)-N-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 212142-42-2 CAPLUS


CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 212142-43-3 CAPLUS


CN 1-Phthalazinamine, N-[3-(3,4-dimethoxyphenyl)]-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)



RN 212142-44-4 CAPLUS


CN 1-Phthalazinamine, N-(4-chloro-3-methoxyphenyl)-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-45-5 CAPLUS


CN 1,3-Benzenediamine, N,N-dimethyl-N'-[4-(4-pyridinylmethyl)-1-phthalazinyl]-
(9CI) (CA INDEX NAME)



RN 212142-46-6 CAPLUS


CN Acetamide, N-[3-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-47-7 CAPLUS


CN 1-Phthalazinamine, N-[3-(2-methyl-4-pyrimidinyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212142-48-8 CAPLUS


CN 1-Phthalazinamine, N-[1,1'-biphenyl]-3-yl-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 212142-49-9 CAPLUS


CN Boronic acid, [3-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]phenyl]-
(9CI) (CA INDEX NAME)



RN 212142-50-2 CAPLUS


CN Benzoic acid, 3-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]-, ethyl
ester (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-51-3 CAPLUS


CN Phenol, 3-methyl-4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI)
(CA INDEX NAME)



RN 212142-52-4 CAPLUS


CN 1-Phthalazinamine, N-[3-(methoxysulfonyl)phenyl]-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-53-5 CAPLUS


CN 1-Phthalazinamine, N-[3-(phenylsulfonyl)phenyl]-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 212142-54-6 CAPLUS


CN 1-Phthalazinamine, N-[3-(phenyloxy)phenyl]-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 212142-55-7 CAPLUS


CN 1-Phthalazinamine, N-[3-(5-oxazolyl)phenyl]-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)



RN 212142-56-8 CAPLUS


CN 1-Phthalazinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-57-9 CAPLUS


CN 1-Phthalazinamine, N-(4-fluoro-3-methoxyphenyl)-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)




RN 212142-58-0 CAPLUS

CN 1-Phthalazinamine, N-[3-methyl-4-(1-methylethyl)phenyl]-4-(4-
pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 212142-59-1 CAPLUS
CN Ethanone, 1-[2-hydroxy-4-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 212142-60-4 CAPLUS
CN Benzamide, 3-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-62-6 CAPLUS


CN Ethanone, 1-[3-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]phenyl]- (9CI)
(CA INDEX NAME)



RN 212142-63-7 CAPLUS


CN 1-Phthalazinamine, N-[3-(2-methyl-1,3-dioxolan-2-yl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-64-8 CAPLUS


CN Phenol, 2-chloro-5-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI)
(CA INDEX NAME)




RN 212142-65-9 CAPLUS

CN Phthalazine, 1-(3-chlorophenoxy)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX
NAME)

V. Balasubramanian




RN 212142-66-0 CAPLUS
CN Phthalazine, 1-(4-chlorophenoxy)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 212142-67-1 CAPLUS
CN Phthalazine, 1-(4-methylphenoxy)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 212142-68-2 CAPLUS
CN Phthalazine, 1-(4-methoxyphenoxy)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 212142-69-3 CAPLUS
CN Phthalazine, 1-[(4-chlorophenyl)thio]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 212142-74-0 CAPLUS
CN 1-Phthalazinemethanol, 4-[(4-chlorophenyl)amino]-.alpha.-4-pyridinyl-,
benzoate (ester) (9CI) (CA INDEX NAME)




RN 212142-75-1 CAPLUS
CN 1-Phthalazinemethanol, 4-[(4-chlorophenyl)amino]-.alpha.-4-pyridinyl-,
(9CI) (CA INDEX NAME)

V. Balasubramanian




RN 212142-81-9 CAPLUS
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 212142-82-0 CAPLUS
CN 1-Phthalazinamine, N-phenyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



L4 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 1997:275859 CAPLUS
DN 126:338957
TI New indolyl phthalazinones and phthalazine derivatives as spermicidal agents
AU Kidwai, Mazaahir; Negi, Neena; Kohli, Seema
CS Department of Chemistry, University of Delhi, Delhi, 110007, India
SO Acta Pharm. (Zagreb) (1997), 47(1), 53-57
CODEN: ACPHEE; ISSN: 1330-0075
PB Croatian Pharmaceutical Society
DT Journal
LA English
IT **190000-08-9P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(indolylphthalazinones and phthalazine derivs. prepn. as spermicidal agents)
RN 190000-08-9 CAPLUS
CN 1-Phthalazinamine, 4-(1H-indol-3-ylmethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2002 ACS

V. Balasubramanian

AN 1996:401561 CAPLUS
 DN 125:58530
 TI Preparation of phthalazine derivatives as cyclic GMP phosphodiesterase inhibitors
 IN Watanabe, Nobuhisa; Kabasawa, Yasuhiro; Takase, Yasutaka; Ozaki, Fumihiro; Ishibashi, Keiji; Miyazaki, Kazuki; Matsukura, Masayuki; Souda, Shigeru; Miyake, Kazutoshi; et al.
 PA Eisai Co., Ltd., Japan
 SO PCT Int. Appl., 113 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9605176	A1	19960222	WO 1995-JP1575	19950808
	W: AU, CA, CN, FI, HU, KR, MX, NO, NZ, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2173493	AA	19960222	CA 1995-2173493	19950808
	AU 9531919	A1	19960307	AU 1995-31919	19950808
	AU 705229	B2	19990520		
	EP 722936	A1	19960724	EP 1995-927990	19950808
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1135210	A	19961106	CN 1995-190862	19950808
	HU 76067	A2	19970630	HU 1996-933	19950808
	HU 219864	B	20010828		
	RU 2128175	C1	19990327	RU 1996-115026	19950808
	JP 08225541	A2	19960903	JP 1995-203102	19950809
	FI 9601510	A	19960529	FI 1996-1510	19960403
	NO 9601397	A	19960606	NO 1996-1397	19960409
	US 5849741	A	19981215	US 1996-619621	19960409
	US 6218392	B1	20010417	US 1998-161946	19980929
PRAI	JP 1994-187128	A	19940809		
	JP 1994-316337	A	19941220		
	WO 1995-JP1575	W	19950808		
	US 1996-619621	A3	19960409		
IT	178309-30-3P 178309-31-4P				
	RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of phthalazine derivs. as cyclic GMP phosphodiesterase inhibitors)				
RN	178309-30-3 CAPLUS				
CN	1-Phthalazinamine, 6-chloro-N-[(3-chloro-4-methoxyphenyl)methyl]-4-(3-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)				

V. Balasubramanian



RN 178309-31-4 CAPLUS

CN 1-Phthalazinamine, 7-chloro-N-[(3-chloro-4-methoxyphenyl)methyl]-4-(3-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 1994:457434 CAPLUS

DN 121:57434

TI Synthesis and structure-activity relationships of 1-aminophthalazinium salts as GABAA receptor antagonists

V. Balasubramanian

TI New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis

AU Bold, Guido; Altmann, Karl-Heinz; Frei, Joerg; Lang, Marc; Manley, Paul W.; Traxler, Peter; Wietfeld, Bernhard; Brueggen, Josef; Buchdunger, Elisabeth; Cozens, Robert; Ferrari, Stefano; Furet, Pascal; Hofmann, Francesco; Martiny-Baron, Georg; Mestan, Juergen; Roesel, Johannes; Sills, Matthew; Stover, David; Acemoglu, Figan; Boss, Eugen; Emmenegger, Rene; Laesser, Laurent; Masso, Elvira; Roth, Rosemarie; Schlachter, Christian; Vetterli, Werner; Wyss, Dominique; Wood, Jeanette M.

CS Oncology Research and Process Research, NOVARTIS Pharma AG, Basel, CH-4002, Switz.

SO Journal of Medicinal Chemistry (2000), 43(12), 2310-2323
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

IT **212142-18-2P**, CGP 79787D
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(prepn. of anilinophthalazines as inhibitors of VEGF receptor tyrosine kinase)


RN 212142-18-2 CAPLUS

CN Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 212141-54-3

CMF C20 H15 Cl N4



CM 2

V. Balasubramanian

CRN 110-15-6
CMF C4 H6 O4


HO₂C-CH₂-CH₂-CO₂H

IT 212141-56-5P 212141-60-1P 212141-68-9P
212141-72-5P 212141-92-9P 212142-02-4P
212142-05-7P 212142-11-5P 212142-38-6P
212142-40-0P 212142-44-4P 212142-56-8P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(prepn. of anilinophthalazines as inhibitors of VEGF receptor tyrosine kinase)

RN 212141-56-5 CAPLUS

CN 1-Phthalazinamine, N-phenyl-4-(4-pyridinylmethyl)-, dihydrochloride (9CI)
(CA INDEX NAME)




●2 HCl

RN 212141-60-1 CAPLUS


CN 1-Phthalazinamine, N-(3-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-68-9 CAPLUS


CN Phenol, 3-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA INDEX NAME)




RN 212141-72-5 CAPLUS

CN 1-Phthalazinamine, N-(3,4-dichlorophenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian




RN 212141-92-9 CAPLUS
CN 1-Phthalazinamine, N-(3-methylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)




RN 212142-02-4 CAPLUS
CN 1-Phthalazinamine, N-(3,5-dimethylphenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 212142-05-7 CAPLUS


CN 1-Phthalazinamine, N-[4-(1,1-dimethylethyl)phenyl]-4-(4-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 212142-11-5 CAPLUS


CN 1-Phthalazinamine, N-[1,1'-biphenyl]-4-yl-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)

V. Balasubramanian



RN 212142-38-6 CAPLUS


CN 1-Phthalazinamine, N-[3-bromo-5-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212142-40-0 CAPLUS


CN 1-Phthalazinamine, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-44-4 CAPLUS


CN 1-Phthalazinamine, N-(4-chloro-3-methoxyphenyl)-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 212142-56-8 CAPLUS

CN 1-Phthalazinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




IT 212141-54-3P, CGP 79787

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of anilinophthalazines as inhibitors of VEGF receptor tyrosine
kinase)

RN 212141-54-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)



IT 137387-83-8P 212141-98-5P 212141-99-6P
212142-20-6P 212142-22-8P 212142-66-0P
212142-69-3P 284031-05-6P 284031-06-7P


V. Balasubramanian

284031-07-8P 284031-08-9P 284031-11-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of anilinophthalazines as inhibitors of VEGF receptor tyrosine kinase)


RN 137387-83-8 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212141-98-5 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[(2-methyl-4-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 212141-99-6 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[(2,6-dimethyl-4-pyridinyl)methyl]-
(9CI) (CA INDEX NAME)



RN 212142-20-6 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[1-(4-pyridinyl)ethyl]- (9CI) (CA
INDEX NAME)




RN 212142-22-8 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyrimidinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian




RN 212142-66-0 CAPLUS
CN Phthalazine, 1-(4-chlorophenoxy)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 212142-69-3 CAPLUS
CN Phthalazine, 1-[(4-chlorophenyl)thio]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 284031-05-6 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-N-methyl-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)




RN 284031-06-7 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(2-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian




RN 284031-07-8 CAPLUS
CN 1,7-Phthalazinediamine, N1-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)




RN 284031-08-9 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-7-methyl-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)

V. Balasubramanian



RN 284031-11-4 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-6-methyl-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)




IT **212141-51-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of anilinophthalazines as inhibitors of VEGF receptor tyrosine kinase)

RN 212141-51-0 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)

V. Balasubramanian



CM 2

CRN 110-15-6
CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 2000:509389 CAPLUS
DN 134:216785
TI New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. [Erratum to document cited in CA133:99079]
AU Bold, Guido; Altmann, Karl-Heinz; Frei, Joerg; Lang, Marc; Manley, Paul W.; Traxler, Peter; Wietfeld, Bernhard; Brueggen, Josef; Buchdunger, Elisabeth; Cozens, Robert; Ferrari, Stefano; Furet, Pascal; Hofmann, Francesco; Martiny-Baron, Georg; Mestan, Juergen; Roesel, Johannes; Sills, Matthew; Stover, David; Acemoglu, Figan; Boss, Eugen; Emmenegger, Rene; Laesser, Laurent; Masso, Elvira; Roth, Rosemarie; Schlachter, Christian; Vetterli, Werner; Wyss, Dominique; Wood, Jeanette M.
CS Oncology Research and Process Research, NOVARTIS Pharma AG, Basel, CH-4002, Switz.
SO J. Med. Chem. (2000), 43(16), 3200
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT **212142-18-2P**, CGP 79787D
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic

V. Balasubramanian

use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(prepn. of anilinophthalazines as inhibitors of VEGF receptor tyrosine kinase' (Erratum))


RN 212142-18-2 CAPLUS

CN Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 212141-54-3

CMF C20 H15 Cl N4



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO₂C-CH₂-CH₂-CO₂H

IT 212141-56-5P 212141-60-1P 212141-68-9P

212141-72-5P 212141-92-9P 212142-02-4P

212142-05-7P 212142-11-5P 212142-38-6P

212142-40-0P 212142-44-4P 212142-56-8P


RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)

(prepn. of anilinophthalazines as inhibitors of VEGF receptor tyrosine kinase (Erratum))

RN 212141-56-5 CAPLUS

CN 1-Phthalazinamine, N-phenyl-4-(4-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


V. Balasubramanian



●2 HCl

RN 212141-60-1 CAPLUS


CN 1-Phthalazinamine, N-(3-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212141-68-9 CAPLUS


CN Phenol, 3-[[4-(4-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212141-72-5 CAPLUS


CN 1-Phthalazinamine, N-(3,4-dichlorophenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)



RN 212141-92-9 CAPLUS


CN 1-Phthalazinamine, N-(3-methylphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 212142-02-4 CAPLUS


CN 1-Phthalazinamine, N-(3,5-dimethylphenyl)-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)



RN 212142-05-7 CAPLUS


CN 1-Phthalazinamine, N-[4-(1,1-dimethylethyl)phenyl]-4-(4-pyridinylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-11-5 CAPLUS


CN 1-Phthalazinamine, N-[1,1'-biphenyl]-4-yl-4-(4-pyridinylmethyl)- (9CI)
(CA INDEX NAME)



RN 212142-38-6 CAPLUS


CN 1-Phthalazinamine, N-[3-bromo-5-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-40-0 CAPLUS


CN 1-Phthalazinamine, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 212142-44-4 CAPLUS


CN 1-Phthalazinamine, N-(4-chloro-3-methoxyphenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 212142-56-8 CAPLUS

CN 1-Phthalazinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




IT 212141-54-3P, CGP 79787

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of anilinophthalazines as inhibitors of VEGF receptor tyrosine
kinase (Erratum))

RN 212141-54-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian




IT 137387-83-8P 212141-98-5P 212141-99-6P
212142-20-6P 212142-22-8P 212142-66-0P
212142-69-3P 284031-05-6P 284031-06-7P
284031-07-8P 284031-08-9P 284031-11-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of anilinophthalazines as inhibitors of VEGF receptor tyrosine kinase (Erratum))

RN 137387-83-8 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 212141-98-5 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[(2-methyl-4-pyridinyl)methyl]-
(9CI) (CA INDEX NAME)



RN 212141-99-6 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[(2,6-dimethyl-4-pyridinyl)methyl]-
(9CI) (CA INDEX NAME)




RN 212142-20-6 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[1-(4-pyridinyl)ethyl]- (9CI) (CA
INDEX NAME)

V. Balasubramanian




RN 212142-22-8 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




RN 212142-66-0 CAPLUS
CN Phthalazine, 1-(4-chlorophenoxy)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 212142-69-3 CAPLUS
CN Phthalazine, 1-[(4-chlorophenyl)thio]-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 284031-05-6 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-N-methyl-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 284031-06-7 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 284031-07-8 CAPLUS


CN 1,7-Phthalazinediamine, N1-(4-chlorophenyl)-4-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 284031-08-9 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-7-methyl-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 284031-11-4 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-6-methyl-4-(4-pyridinylmethyl)-
(9CI) (CA INDEX NAME)

V. Balasubramanian




IT 212141-51-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of anilinophthalazines as inhibitors of VEGF receptor tyrosine kinase (Erratum))

RN 212141-51-0 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-,
dihydrochloride (9CI) (CA INDEX NAME)




L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 2000:359936 CAPLUS
DN 133:99079

09/636,519

V. Balasubramanian

AU Colotta, V.; Cecchi, L.; Catarzi, D.; Filacchioni, G.; Galli, A.; Mori, F.
CS Dip. Sci. Farm., Univ. Firenze, Florence, 50121, Italy
SO Eur. J. Med. Chem. (1994), 29(2), 95-105
CODEN: EJMCA5; ISSN: 0223-5234
DT Journal
LA English
IT **155937-32-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and conversion to amine by ammonium acetate)
RN 155937-32-9 CAPLUS
CN Phthalazine, 1-phenoxy-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 1993:649963 CAPLUS
DN 119:249963
TI 3,6-disubstituted pyridazine derivative blood platelet aggregation inhibitors
IN Iwase, Norimichi; Morinaka, Yasuhiro; Tamao, Yoshikuni; Kanayama, Toshiji; Yamada, Kumi
PA Mitsubishi Kasei Corp., Japan
SO Eur. Pat. Appl., 115 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 534443	A1	19930331	EP 1992-116413	19920924
	EP 534443	B1	19981230		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 06135938	A2	19940517	JP 1992-239545	19920908
	JP 2730421	B2	19980325		
	CA 2078699	AA	19930327	CA 1992-2078699	19920921
	AT 175200	E	19990115	AT 1992-116413	19920924
	ES 2128333	T3	19990516	ES 1992-116413	19920924
	US 5324727	A	19940628	US 1992-950947	19920925
	US 5462941	A	19951031	US 1994-215426	19940321
PRAI	JP 1991-247647		19910926		
	JP 1991-335277		19911218		
	JP 1992-239545		19920908		
	US 1992-950947		19920925		
OS	MARPAT 119:249963				
IT	149549-24-6P 149549-25-7P 149549-26-8P				
	149549-27-9P				


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and blood platelet aggregation inhibitory activity of)

V. Balasubramanian

RN 149549-24-6 CAPLUS

CN 1-Phthalazinamine, N-(1-phenylethyl)-4-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 149549-25-7 CAPLUS

CN 1-Phthalazinamine, 4-[(4-chlorophenyl)methyl]-N-(1-cyclohexylethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149549-26-8 CAPLUS

CN 1-Phthalazinamine, 4-phenoxy-N-(1-phenylethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 149549-27-9 CAPLUS

CN 1-Phthalazinamine, N-(1-phenylethyl)-4-(phenylthio)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 1991:656197 CAPLUS

DN 115:256197

TI Preparation of 1-(3-pyridylmethyl)phthalazines as blood platelet aggregation inhibitors

IN Uenishi, Keiji; Kosegi, Koji; Asaumi, Yoshio; Ishizuka, Yasuhiro; Yaginuma, Hideya

PA Morishita Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 6 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03106875	A2	19910507	JP 1989-246074	19890920

OS MARPAT 115:256197

IT 137387-75-8P 137387-76-9P 137387-79-2P

137387-80-5P 137387-81-6P 137387-82-7P

137387-83-8P 137387-84-9P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP


V. Balasubramanian

(Preparation); USES (Uses)

(prepn. of, as blood platelet aggregation inhibitor)


RN 137387-75-8 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 137387-76-9 CAPLUS


CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 137387-79-2 CAPLUS

CN 1-Phthalazinamine, N-phenyl-4-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 137387-80-5 CAPLUS
CN 1-Phthalazinamine, N-(2-fluorophenyl)-4-(3-pyridinylmethyl)- (9CI) (CA
INDEX NAME)




RN 137387-81-6 CAPLUS
CN 1-Phthalazinamine, N-(3-fluorophenyl)-4-(3-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian




RN 137387-82-7 CAPLUS
CN 1-Phthalazinamine, N-(4-fluorophenyl)-4-(3-pyridinylmethyl)- (9CI) (CA
INDEX NAME)




RN 137387-83-8 CAPLUS
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(3-pyridinylmethyl)- (9CI) (CA
INDEX NAME)

V. Balasubramanian



RN 137387-84-9 CAPLUS
CN Phenol, 4-[[4-(3-pyridinylmethyl)-1-phthalazinyl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 1991:449575 CAPLUS
DN 115:49575
TI Synthesis and reactions of 4-aryl-1(2H)-phthalazinones
AU Sayed, M. A.; Islam, I.; Mohamed, A. A.; Soliman, A. Y.; Bakeer, H. M.
CS Fac. Sci., Ain Shams Univ., Egypt
SO Chin. J. Chem. (1991), 9(1), 45-53
CODEN: CJOCEV
DT Journal


09/636,519

V. Balasubramanian

LA English
OS CASREACT 115:49575
IT **134949-72-7P 134949-73-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 134949-72-7 CAPLUS
CN 2-Propenoic acid, 3-(4-methoxyphenyl)-2-[[4-(phenylmethyl)-1-phthalazinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 134949-73-8 CAPLUS
CN 2-Propenoic acid, 3-phenyl-2-[[4-(phenylmethyl)-1-phthalazinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)





L4 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 1990:601457 CAPLUS
DN 113:201457
TI Tetraazaporphine for optical recording material
IN Tai, Seiji; Hayashi, Nobuyuki; Kamijima, Koichi; Katayose, Mitsuo;
Akimoto, Takayuki; Hagiwara, Hideo
PA Hitachi Chemical Co., Ltd., Japan
SO Eur. Pat. Appl., 465 pp.
CODEN: EPXXDW

V. Balasubramanian

DT Patent
LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 344891	A2	19891206	EP 1989-303355	19890405
	EP 344891	A3	19910410		
	EP 344891	B1	19940727		
	R: DE, GB				
	CA 1337194	A1	19951003	CA 1989-595610	19890404
	US 5217856	A	19930608	US 1989-334290	19890406
	JP 02276866	A2	19901113	JP 1989-89448	19890407
	US 5284943	A	19940208	US 1992-824582	19920122
PRAI	JP 1988-85965		19880407		
	JP 1988-166349		19880704		
	JP 1988-166350		19880704		
	JP 1988-175381		19880714		
	JP 1988-214572		19880829		
	JP 1988-277969		19881102		
	JP 1988-280558		19881107		
	JP 1988-280559		19881107		
	JP 1988-280560		19881107		
	JP 1988-308545		19881206		
	JP 1989-17151		19890126		
	JP 1989-17152		19890126		
	JP 1989-17153		19890126		
	JP 1989-17154		19890126		
	JP 1989-17155		19890126		
	JP 1989-17156		19890126		
	JP 1989-17157		19890126		
	JP 1989-17158		19890126		
	JP 1989-17159		19890126		
	US 1989-334290		19890406		
OS	MARPAT 113:201457				
IT	127008-70-2				
	RL: TEM (Technical or engineered material use); USES (Uses)				
	(optical recording material contg.)				
RN	127008-70-2 CAPLUS				
CN	Silicon, [1,4,10,13,19,22,28,31-octaphenoxy-37H,39H-tetraphthalazino[6,7-b:6',7'-g:6'',7''-l:6''',7'''-q]porphyrazinato(2-)-N37,N38,N39,N40]bis(tributylsilanolato)-, (OC-6-12)- (9CI) (CA INDEX NAME)				



L4 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2002 ACS
 AN 1976:179558 CAPLUS
 DN 84:179558
 TI Hydrazones. XL. Spectra and structure of 1-hydrazinophthalazines
 AU Buzykin, B. I.; Bystrykh, N. N.; Stolyarov, A. P.; Flegontov, S. A.;
 Zverev, V. V.; Kitaev, Yu. P.
 CS Inst. Org. Fiz. Khim. im. Arbuzova, Kazan, USSR
 SO Khim. Geterotsikl. Soedin. (1976), (3), 402-9
 CODEN: KGSSAQ
 DT Journal
 LA Russian
 IT **21415-73-6**
 RL: PRP (Properties)
 (spectra of)
 RN 21415-73-6 CAPLUS
 CN Phthalazine, 1,4-diphenoxy- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

V. Balasubramanian



L4 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 1971:22865 CAPLUS
DN 74:22865
TI Pharmaceutical 1-amino-4-phenylphthalazines
IN Rodway, Ronald E.; Simmonds, Robin G.
PA Aspro-Nicholas Ltd.
SO Ger. Offen., 28 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2021195	A	19701112	DE 1970-2021195	19700430
	GB 1293565	A	19721018	GB 1969-22679	19690503
	FR 2043504	A1	19710219	FR 1970-15663	19700429
	FR 2043504	A5	19710219		
	SE 376916	B	19750616	SE 1970-5984	19700429
	BE 749824	A	19701030	BE 1970-749824	19700430
	US 3753988	A	19730821	US 1970-33506	19700430
	CH 523890	A	19720615	CH 1970-523890	19700502
	JP 48039944	B4	19731128	JP 1970-38184	19700504
PRAI	GB 1969-22679		19690503		

IT **23069-68-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 23069-68-3 CAPLUS


CN Phthalazine, 1-benzyl-4-(cyclopropylamino)- (8CI) (CA INDEX NAME)



L4 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 1971:3381 CAPLUS

V. Balasubramanian

DN 74:3381
TI Nucleophilic aromatic substitution by aminophenoxide ions
AU Schramm, Juergen; Radlmann, Eduard; Lohwasser, Hermann; Nischk, Guenther
CS Org.-Wiss. Lab., Farbenfabriken Bayer A.-G., Dormagen/Rhein, Ger.
SO Justus Liebig's Ann. Chem. (1970), 740, 169-79
CODEN: JLACBF
DT Journal
LA German
IT **30203-09-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 30203-09-9 CAPLUS
CN Phthalazine, 1,4-bis(p-aminophenoxy)- (8CI) (CA INDEX NAME)



L4 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2002 ACS

AN 1969:512963 CAPLUS

DN 71:112963

TI 1-Hydroxyaminophthalazines

PA Vantorex Ltd.

SO Fr., 5 pp.

CODEN: FRXXAK

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 1532163		19680705	FR	19670725

IT **21415-73-6P**


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 21415-73-6 CAPLUS


CN Phthalazine, 1,4-diphenoxy- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

09/636,519

V. Balasubramanian



L4 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 1969:422093 CAPLUS
DN 71:22093
TI 1-Substituted 4-aryl-(or 4-aralkyl-)phthalazines
AU Holava, H. M., Jr.; Partyka, R. A.
CS Bristol Lab. Div., Bristol-Myers Co., Syracuse, N. Y., USA
SO J. Med. Chem. (1969), 12, 555-6
CODEN: JMCMAR
DT Journal
LA English
IT **23069-68-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 23069-68-3 CAPLUS
CN Phthalazine, 1-benzyl-4-(cyclopropylamino)- (8CI) (CA INDEX NAME)



L4 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2002 ACS
AN 1969:57872 CAPLUS
DN 70:57872
TI Substituted 1-amino phthalazines
IN Parsons, David G.; Turner, Alan F.; Murray, Brian G.
PA Vantorex Ltd.
SO Brit., 14 pp. Addn. to Brit. 1094044
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1133406		19681113	GB	19670626


V. Balasubramanian

IT 21415-73-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 21415-73-6 CAPLUS

CN Phthalazine, 1,4-diphenoxy- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

103.52

244.53

STN INTERNATIONAL LOGOFF AT 16:06:08 ON 21 FEB 2002

Connection closed by remote host